Opinion|Videos|August 23, 2024
Role of Biologics in Dermatological Care
A key opinion leader examines how the introduction of biologic therapies revolutionized atopic dermatitis treatment, addressing strategies to manage patients' concerns about needles and injections.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- How have the emergence of biologics changed the treatment landscape of these diseases caused by an overactive immune response?
- How do you approach presenting monoclonal antibody treatments to patients or caregivers who have an apprehension of needles or injections? What strategies do you use to alleviate their concerns and gain their trust in proceeding with this preferred treatment option?
Advertisement
Related to this article
Michael Mina, MD, PhD, explains which adverse events drove VYD2311's edge vs an mRNA COVID-19 vaccine and who may benefit most.
Cepheid's Connie Savor, MD, MBA, explains where its 13-pathogen respiratory panel fits in diagnostic stewardship and antibiotic decisions.
The FDA approves atezolizumab with a fluoropyrimidine and oxaliplatin as adjuvant therapy for stage III dMMR colon cancer based on the ATOMIC trial.
Michael Mina, MD, PhD, explains Invivyd's accelerated approval path for VYD2311 and how it could change the timing of COVID-19 protection.
Biomarker-driven care is advancing in mantle cell lymphoma, though cost and infrastructure limit access in community oncology, according to a review.
Fibrosis stage, not MASH resolution, best predicts mortality, which should shape trial end points, says Georgetown's Zobair Younossi, MD, MPH.
Remibrutinib (Rhapsido; Novartis) is the only treatment with approved uses in both chronic spontaneous urticaria and symptomatic dermographism.
Lean MASLD shows milder histology than overweight and obese MASLD but similar mortality and event risk, with fibrosis tied to prognosis.
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Once-Monthly Subcutaneous Olanzapine for Schizophrenia
2
Timing COVID-19 Protection With VYD2311: Michael Mina, MD, PhD
3
FDA Approves IV, Subcutaneous Atezolizumab for dMMR Colon Cancer
4
Bumetanide Nasal Spray Targets Heart Failure Edema Before IV
5